Before starting Obesema 1.7mg Injection (1 Multi-dose Disposable Pen, 4 Needles, 4 Alcohol Swabs), inform your doctor about any medical conditions you have, particularly a history of pancreatitis, eye problems caused by diabetes (diabetic retinopathy), thyroid cancer, or severe gastrointestinal problems
The first phase 3 retatrutide trial, TRIUMPH-4, top-line data announced today Retatrutide, a triple GLP-1,GIP, glucagon agonist studied in patients with obesity and osteoarthritis 28.7% weight loss at 68 weeks Reduced key cardiometabolic risk markers non-HDL cholesterol, triglycerides, and hsCRP Highest dose lowered systolic BP by 14 mmHg Reduced WOMAC pain scores by up to an average of 4.5 points (75.8%) and significantly improved measures of physical function GI side effects most common adverse event We now await 7 additional phase 3 trials in other obesity related comorbidities Retatrutide May Redefine Multi-Receptor Therapeutics Triple agonism (GLP-1 + GIP + glucagon) isnt just about adding more receptors this distinct mechanism can boost energy expenditure, not just suppress appetite
Mistake 2: No exit strategy Starting phentermine without a predefined discontinuation plan leads to indefinite use of a drug approved for only 12 weeks
Is losing 10 pounds a month a realistic goal
Archived from the original on 10 January 2007
